Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II
about
Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.Differential expression of PDE5 in failing and nonfailing human myocardiumRight ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.Compartmentalization of beta-adrenergic signals in cardiomyocytes.Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs.Chronic vasodilation increases renal medullary PDE5A and α-ENaC through independent renin-angiotensin-aldosterone system pathwaysCyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.Phosphodiesterases and cyclic GMP regulation in heart muscle.Heart selenoproteins status of metabolic syndrome-exposed pups: A potential target for attenuating cardiac damage.The enigma of continual plasma volume expansion in pregnancy: critical role of the renin-angiotensin-aldosterone system.Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy.Generation and phenotypic characterization of Pde1a mutant mice.Sustained exposure to catecholamines affects cAMP/PKA compartmentalised signalling in adult rat ventricular myocytes.The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders.C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.Soluble adenylyl cyclase: A novel player in cardiac hypertrophy induced by isoprenaline or pressure overload.Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity.
P2860
Q33966155-064193DE-9E29-40D1-872F-62C38F278D7CQ34953389-9351EE72-176A-4269-A6C1-88450E6661FAQ35181565-29CDAB89-88CC-4DCA-97E3-490D9CDE163EQ35680934-4AF34B2E-4E9B-410C-8BC6-E724BC5AC0D5Q35749616-BF2C2298-F993-43BF-95A9-9EC6D59307B3Q36384788-0D575BE5-1203-4234-8EBE-BA133C6E2C27Q36810706-A8598EF9-A8BF-4825-9346-182DBD676F10Q37346049-D4515F05-BE65-453F-A943-A18A43FCB690Q37947681-3BEC682B-3B9A-4713-BE1B-8F6F682229DAQ38033089-DD174BE5-174B-4F88-B41B-5E5CA2A7963FQ38831748-145867BB-DA9A-4912-AAC5-25F826241D68Q38973055-F1E95E9A-D340-4EBA-BC45-436B829F59B7Q40813682-3752796F-3907-4F5F-816E-3BB6FA4BBB87Q41153428-270C8DAF-4D39-4ACE-AD20-F6A3A4165864Q42777336-9872BA11-EDB7-48A6-A974-55C516332EC4Q45068634-5D58013A-F25E-4EDC-8359-FC9C5A1D8C4FQ47987941-599B744F-7E51-4454-AE53-5EE9B14B85C7Q52692039-82CE432A-3FA1-4ACC-890C-DA1CE5BC044EQ55341491-B8E151FC-97D0-4D55-ADAD-6C3226F5B216
P2860
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Concerted regulation of cGMP a ...... ophy induced by angiotensin II
@ast
Concerted regulation of cGMP a ...... ophy induced by angiotensin II
@en
type
label
Concerted regulation of cGMP a ...... ophy induced by angiotensin II
@ast
Concerted regulation of cGMP a ...... ophy induced by angiotensin II
@en
prefLabel
Concerted regulation of cGMP a ...... ophy induced by angiotensin II
@ast
Concerted regulation of cGMP a ...... ophy induced by angiotensin II
@en
P2093
P2860
P1433
P1476
Concerted regulation of cGMP a ...... ophy induced by angiotensin II
@en
P2093
Alison Walter
Claire Lugnier
Modou O Kane
Nelly Etienne-Selloum
Thérèse Keravis
Valérie B Schini-Kerth
Walid Mokni
P2860
P304
P356
10.1371/JOURNAL.PONE.0014227
P407
P577
2010-12-03T00:00:00Z